A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

Abroad (travel likely)RecruitingPHASE3

Conditions

Facioscapulohumeral Muscular Dystrophy · FSHD · FSHD - Facioscapulohumeral Muscular Dystrophy · FSHD1 · FSHD2 · Fascioscapulohumeral Muscular Dystrophy · Fascioscapulohumeral Muscular Dystrophy Type 1 · Fascioscapulohumeral Muscular Dystrophy Type 2 · Facioscapulohumeral Muscular Dystrophy 1 · Facioscapulohumeral Dystrophy · Facio-Scapulo-Humeral Dystrophy · Facioscapulohumeral Muscular Dystrophy 2 · Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) · FSH Muscular Dystrophy · Landouzy Dejerine Dystrophy · Landouzy-Dejerine Muscular Dystrophy · Landouzy-Dejerine Syndrome

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University of California Irvine, Orange, California, United States

  • Stanford University, Palo Alto, California, United States

  • University of Colorado, Denver, Colorado, United States

  • University of Florida, Gainesville, Florida, United States

  • University of Iowa, Iowa City, Iowa, United States

  • Kansas University Medical Center, Kansas City, Kansas, United States

  • Kennedy Krieger Institute, Baltimore, Maryland, United States

  • University of Massachusetts, Worcester, Massachusetts, United States

  • University of Rochester Medical Center, Rochester, New York, United States

  • Duke University, Durham, North Carolina, United States

  • Ohio State University, Columbus, Ohio, United States

  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

  • University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

  • Virginia Commonwealth University, Richmond, Virginia, United States

  • University of Calgary - Cumming School of Medicine, Calgary, Alberta, Canada

  • University of Alberta Hospital, Edmonton, Alberta, Canada

  • The Ottawa Hospital, Ottawa, Ontario, Canada

  • Genge Partners Inc, Montreal, Quebec, Canada

  • Aarhus University Hospital, Aarhus, Denmark

  • Rigshospitalet, Copenhagen, Denmark

  • Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone, Marseille, France

  • CHU de Montpellier - Hopital Gui de Chauliac, Montpellier, France

  • CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires, Nice, France

  • AP-HP Hopital Pitie-Salpetriere, Paris, France

  • Universitaetsklinikum Bonn, Bonn, Germany

  • Georg-August-Universitaet Goettingen Stiftung oeffentlichen Rechts Universitaetsmedizin Goettingen, Göttingen, Germany

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München, Germany

  • Universitaetsklinikum Ulm, Ulm, Germany

  • Fondazione Serena ETS - Centro Clinico NeMO Milano, Milan, Italy

  • Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  • Azienda Ospedaliero-Universitaria Sant'Andrea, Roma, Italy

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Italy

  • National Hospital Organization Osaka Toneyama Medical Center, Osaka, Japan

  • The University of Osaka Hospital, Osaka, Japan

  • National Hospital Organization Sendai Nishitaga Hospital, Sendai, Japan

  • National Center of Neurology and Psychiatry, Tokyo, Japan

  • Academisch Ziekenhuis Leiden, Leiden, Netherlands

  • Stichting Radboud Universitair Medisch Centrum, Nijmegen, Netherlands

  • Hospital Universitari de Bellvitge, Barcelona, Spain

  • Hospital Universitario Vall d'Hebron, Barcelona, Spain

  • Hospital Universitario Donostia, San Sebastián, Spain

  • Hospital Universitari i Politecnic La Fe, Valencia, Spain

  • National Hospital for Neurology & Neurosurgery, London, United Kingdom

  • St. George's University Hospitals NHS Foundation Trust, London, United Kingdom

  • Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom

  • Royal Hallamshire Hospital, Sheffield, United Kingdom